Javascript must be enabled to continue!
Completeness of spontaneously reported adverse drug reactions in 4 databases
View through CrossRef
Aims
To assess the completeness of information provided in adverse drug reaction (ADR) reports in 4 spontaneous report databases.
Methods
The study was conducted using freely accessible ADR reports from the Canada Vigilance Adverse Reaction Online Database, the US Food and Drug Administration Adverse Event Reporting System (FAERS) database, the UK Yellow Card Scheme and the Danish Medicines Agency ADR Database, covering the period 2014–2023. The variables used to evaluate the completeness of ADR reports were selected based on the vigiGrade completeness tool. Descriptive statistics were used to report the completeness of information in each ADR report, while chi‐square tests were used to analyse differences in completeness by seriousness of report.
Results
In total, 290 079 individual case safety reports were analysed: 4289 from the Canadian database; 269 763 from the FAERS database; 13 624 from the UK Yellow Card Scheme; and 2403 from the Danish database. The most frequently completed information was the primary reporter, with nearly 100% completeness. The most frequently omitted information was the route of administration, with completion scores of 44% in the UK Yellow Card Scheme, 55% in the Danish database and 58% in the Canadian database. In FAERS, the event date was the most frequently omitted information with a completeness rate of 50%.
Conclusion
The completeness of information varied across different variables, with information frequently omitted for route of administration and event date. Enhancing awareness about providing complete information during ADR reporting is essential for collecting complete data and allowing signal detection.
Title: Completeness of spontaneously reported adverse drug reactions in 4 databases
Description:
Aims
To assess the completeness of information provided in adverse drug reaction (ADR) reports in 4 spontaneous report databases.
Methods
The study was conducted using freely accessible ADR reports from the Canada Vigilance Adverse Reaction Online Database, the US Food and Drug Administration Adverse Event Reporting System (FAERS) database, the UK Yellow Card Scheme and the Danish Medicines Agency ADR Database, covering the period 2014–2023.
The variables used to evaluate the completeness of ADR reports were selected based on the vigiGrade completeness tool.
Descriptive statistics were used to report the completeness of information in each ADR report, while chi‐square tests were used to analyse differences in completeness by seriousness of report.
Results
In total, 290 079 individual case safety reports were analysed: 4289 from the Canadian database; 269 763 from the FAERS database; 13 624 from the UK Yellow Card Scheme; and 2403 from the Danish database.
The most frequently completed information was the primary reporter, with nearly 100% completeness.
The most frequently omitted information was the route of administration, with completion scores of 44% in the UK Yellow Card Scheme, 55% in the Danish database and 58% in the Canadian database.
In FAERS, the event date was the most frequently omitted information with a completeness rate of 50%.
Conclusion
The completeness of information varied across different variables, with information frequently omitted for route of administration and event date.
Enhancing awareness about providing complete information during ADR reporting is essential for collecting complete data and allowing signal detection.
Related Results
Awareness of Adverse Drug Reactions and its Reporting among Third-year Undergraduate Medical Students
Awareness of Adverse Drug Reactions and its Reporting among Third-year Undergraduate Medical Students
Background: Drug is a double-edged sword. Though important, Adverse Drug Reactions under-reporting is real and is mainly due to lack of awareness. No published research has ever ev...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Studi Literatur Kasus Adverse Drug Reactions Dari Pengaruh Bahan Eksipien Obat
Studi Literatur Kasus Adverse Drug Reactions Dari Pengaruh Bahan Eksipien Obat
Abstract. Adverse Drug Reactions (ADRs) are generally triggered by active substances contained in the drugs used, but it is possible that these ADR events are caused and triggered ...
Selection of Injectable Drug Product Composition using Machine Learning Models (Preprint)
Selection of Injectable Drug Product Composition using Machine Learning Models (Preprint)
BACKGROUND
As of July 2020, a Web of Science search of “machine learning (ML)” nested within the search of “pharmacokinetics or pharmacodynamics” yielded over 100...
Complex Collision Tumors: A Systematic Review
Complex Collision Tumors: A Systematic Review
Abstract
Introduction: A collision tumor consists of two distinct neoplastic components located within the same organ, separated by stromal tissue, without histological intermixing...
Isolation, characterization and semi-synthesis of natural products dimeric amide alkaloids
Isolation, characterization and semi-synthesis of natural products dimeric amide alkaloids
Isolation, characterization of natural products dimeric amide alkaloids from roots of the Piper chaba Hunter. The synthesis of these products using intermolecular [4+2] cycloaddit...
Post-marketing safety surveillance and re-evaluaiton of Shu-Xue-Ning injection: a real-world study based on 30,122 cases
Post-marketing safety surveillance and re-evaluaiton of Shu-Xue-Ning injection: a real-world study based on 30,122 cases
Objective: This study aims to investigate the safety of Shu-Xue-Ning injection (SXNI) in real-world clinical applications.Methods: A prospective, multi-center, large-sample intensi...
Pembrolizumab and Sarcoma: A meta-analysis
Pembrolizumab and Sarcoma: A meta-analysis
Abstract
Introduction: Pembrolizumab is a monoclonal antibody that promotes antitumor immunity. This study presents a systematic review and meta-analysis of the efficacy and safety...

